December 8, 2025BiomedicinesOpen Access

Advanced Cutaneous Squamous Cell Carcinoma: Biology, Immunotherapy, and Evolving Prognostic Factors

View Full Paper

Ask AI

Bookmark

Response rates with immune checkpoint inhibitors range from 45-60% for treating advanced cutaneous squamous cell carcinoma.
Observational studies reveal substantial morbidity and mortality, stressing the need for refined prognostic determinants.
Clinical trials confirm the importance of staging and therapeutic strategies in managing metastatic disease.
Significant healthcare costs are associated with advanced cutaneous squamous cell carcinoma treatment, indicating prioritization of risk stratification.

Discussion

No takes yet. Share an insight, caveat, or question.

Narrative review highlights immune checkpoint inhibitors efficacy and ongoing challenges in advanced cutaneous squamous cell carcinoma management.

Guardo et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Narrative review highlights immune checkpoint inhibitors efficacy and ongoing challenges in advanced cutaneous squamous cell carcinoma management.